AR079975A1 - Agentes terapeuticos derivados de bisfenol u metodos para su uso, composiciones farmaceuticas y uso de los mismos - Google Patents
Agentes terapeuticos derivados de bisfenol u metodos para su uso, composiciones farmaceuticas y uso de los mismosInfo
- Publication number
- AR079975A1 AR079975A1 ARP110100035A ARP110100035A AR079975A1 AR 079975 A1 AR079975 A1 AR 079975A1 AR P110100035 A ARP110100035 A AR P110100035A AR P110100035 A ARP110100035 A AR P110100035A AR 079975 A1 AR079975 A1 AR 079975A1
- Authority
- AR
- Argentina
- Prior art keywords
- independently
- formula
- unsubstituted
- acyl
- alkyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 229930185605 Bisphenol Natural products 0.000 title 1
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 8
- 125000002252 acyl group Chemical group 0.000 abstract 8
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 5
- 101100329534 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) csg1 gene Proteins 0.000 abstract 4
- 229910006069 SO3H Inorganic materials 0.000 abstract 4
- 101100422777 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SUR1 gene Proteins 0.000 abstract 4
- AOJDZKCUAATBGE-UHFFFAOYSA-N bromomethane Chemical compound Br[CH2] AOJDZKCUAATBGE-UHFFFAOYSA-N 0.000 abstract 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 4
- HFPGRVHMFSJMOL-UHFFFAOYSA-N dibromomethane Chemical compound Br[CH]Br HFPGRVHMFSJMOL-UHFFFAOYSA-N 0.000 abstract 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 4
- 229920006395 saturated elastomer Polymers 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 abstract 4
- 102100030794 Conserved oligomeric Golgi complex subunit 1 Human genes 0.000 abstract 3
- 101000920124 Homo sapiens Conserved oligomeric Golgi complex subunit 1 Proteins 0.000 abstract 3
- 125000004122 cyclic group Chemical group 0.000 abstract 3
- XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical compound N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 abstract 2
- 101100294106 Caenorhabditis elegans nhr-3 gene Proteins 0.000 abstract 2
- 101100294115 Caenorhabditis elegans nhr-4 gene Proteins 0.000 abstract 2
- 101100516554 Caenorhabditis elegans nhr-5 gene Proteins 0.000 abstract 2
- 101100516563 Caenorhabditis elegans nhr-6 gene Proteins 0.000 abstract 2
- 102100035249 Carbonyl reductase [NADPH] 3 Human genes 0.000 abstract 2
- 101000737274 Homo sapiens Carbonyl reductase [NADPH] 3 Proteins 0.000 abstract 2
- 102000001307 androgen receptors Human genes 0.000 abstract 2
- 108010080146 androgen receptors Proteins 0.000 abstract 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- ROWMQJJMCWDJDT-UHFFFAOYSA-N tribromomethane Chemical compound Br[C](Br)Br ROWMQJJMCWDJDT-UHFFFAOYSA-N 0.000 abstract 2
- 208000002874 Acne Vulgaris Diseases 0.000 abstract 1
- 201000004384 Alopecia Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010014733 Endometrial cancer Diseases 0.000 abstract 1
- 206010014759 Endometrial neoplasm Diseases 0.000 abstract 1
- 206010020112 Hirsutism Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 206010000496 acne Diseases 0.000 abstract 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000024963 hair loss Diseases 0.000 abstract 1
- 230000003676 hair loss Effects 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 208000025661 ovarian cyst Diseases 0.000 abstract 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract 1
- 208000006155 precocious puberty Diseases 0.000 abstract 1
- ZBZJXHCVGLJWFG-UHFFFAOYSA-N trichloromethyl(.) Chemical compound Cl[C](Cl)Cl ZBZJXHCVGLJWFG-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/257—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings
- C07C43/295—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings containing hydroxy or O-metal groups
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicacion 1: Un compuesto que tiene la estructura de formula (1) o una sal farmacéuticamente aceptable de dicho compuesto, en donde X es C=O, C(OH)2, C(OR1)2, C(OH)(OR1), C(OR1)(OR2), O, S, SO, C=NOH, C=NR1, CHNH2, CHNHR1, CHNHR2, CHNR12, CHNR22 o CHNR1R2; cada R1 es independientemente alquilo C1-10 lineal o ramificado, sustituido o no sustituido, saturado o insaturado, y cada R2 es independientemente acilo C1-10, o dos de los grupos R1 se unen para formar un cetal cíclico, en donde el sustituyente opcional se puede seleccionar del grupo que consiste en oxo, OJö' COOH, R3, OH, OR3, F, CI, Br, I, NH2, NHR3, NR32, CN, SH, SR3, SO3H, SO3R3, SO2R3, OSO3R3, OR6, CO2R3, CONH2, CONHR3, CONHR6, CONR32, NHR6, OPO3H3, CONR3R6, NR3R6, y NO2; cada R3 es independientemente alquilo C1-10 no sustituido; cada R6 es independientemente acilo C1-10; al menos un Z de un anillo aromático es independientemente C-Q, al menos un Z del otro anillo aromático es independientemente C-T, CF, CCI, CBr, CI, COH, CG1, CNH2, CNG12, COSO3H, COPO3H2, CSG1, CSOG1, o CSO2G1, y cada Z restante es independientemente C-T, N, CH, CF, CCI, CBr, CI, COH, CG1, COG1, CNH2, CNHG1, CNG12, COSO3H, COPO3H2, CSG1, CSOG1, o CSO2G1; Q es como en resto de formula (2); J es G1, O, CH2, CHG1, CG12, S, SO, SO2, o NR; M es H, CI, Br, CH2CI, CHCI2, CCI3, CH2Br, CHBr2, CBr3, o C:::CH; L es H o A-D; A es O, S, NH, NG1, N+H2, o N+HG1; D es H, G1, R, o como los restos de formulas (3), o un resto seleccionado de la TABLA 1; cada q, r y t es independientemente 0, 1, 2, 3, 4, 5, 6 o 7; n es 0,1, 2, 3, 4, 5, 6, 7 u 8; T es un resto de formula (4); J2 es G1, O, CH2, CHG1, CG12, S, NH, SO, SO2, o NR; M2 es H, CH3, CI, Br, CH2CI, CHCI2, CCI3, CH2Br, CHBr2, CBr3, CH2OH, CH2OJö, G1, CH2OG1, CH2OR, CH2OG1OG1', G1OG1', G1OG1'OG1ö, CH2SG1, CH2NH2, CH2NHG1, CH2NG12, o C:::CH; L2 es H o A2-D2; A2 es O, S, SO, SO2, NH, NG1, N+H2, o N+HG1; D2 es H, G1, R, restos de formulas (3), o un resto seleccionado de la TABLA 1; cada u, y, j es independientemente 0, 1, 2, 3, 4, 5, 6 o 7; m es 0, 1, 2, 3, 4, 5, 6, 7 u 8; cada uno de Jö y Jö' es independientemente un resto seleccionado de la TABLA 1; cada G1, G1' y G1'ö es independientemente alquilo C1-10 lineal o ramificado, sustituido o no sustituido, saturado o insaturado, en donde el sustituyente opcional se puede seleccionar del grupo que consiste en oxo, OJö', COOH, R4, OH, OR4, F, CI, Br, I, NH2, NHR4, NR42, CN, SH, SR4, SO3H, SO3R4, SO2R4, OSO3R4, OR5, CO2R4, CONH2, CONHR4, CONHR5, CONR42, NHR5, OPO3H3, CONR4R5, NR4R5, y NO2; cada R4 es independientemente alquilo C1-10 no sustituido; cada R5 es independientemente acilo C1-10; y R es acilo C1-10. Reivindicacion 41: Una composicion farmacéutica para tratar una o varias de las siguientes afecciones: cáncer de prostata; cáncer de mama; cáncer de ovario; cáncer de endometrio; pérdida de cabello; acné; hirsutismo; quistes ováricos; enfermedad ovárica poliquística; pubertad precoz; y degeneracion macular relacionada con la edad, donde la composicion farmacéutica comprende un compuesto de cualquiera de las reivindicaciones 1-39 y un portador farmacéuticamente aceptable. Reivindicacion 42: El uso de un compuesto que tiene la estructura de formula (1) o una sal farmacéuticamente aceptable de dicho compuesto, en donde X es un enlace simple, C=O, C(OH)2, C(OR1)2, C(OH)(OR1), C(OR1)(OR2), O, S, SO, SO2, C=NOH, C=NR1, CHNH2, CHNHR1, CHNHR2, CHNR12, CHNR22 o CHNR1R2; cada R1 es independientemente alquilo C1-10 lineal o ramificado, sustituido o no sustituido, saturado o insaturado, y cada R2 es independientemente acilo C1-10, o dos de los grupos R1 se unen para formar un cetal cíclico, en donde el sustituyente opcional se puede seleccionar del grupo que consiste en oxo, OJö' COOH, R3, OH, OR3, F, CI, Br, I, NH2, NHR3, NR32, CN, SH, SR3, SO3H, SO3R3, SO2R3, OSO3R3, OR6, CO2R3, CONH2, CONHR3, CONHR6, CONR32, NHR6, OPO3H3, CONR3R6, NR3R6, y NO2; cada R3 es independientemente alquilo C1-10 no sustituido; cada R6 es independientemente acilo C1-10; al menos un Z de un anillo aromático es independientemente C-Q, al menos un Z del otro anillo aromático es independientemente C-T, CF, CCI, CBr, CI, COH, CG1, COG1, CNH2, CNHG1, CNG12, COSO3H, COPO3H2, CSG1, CSOG1 o CSO2G1, y cada Z restante es independientemente C-T, N, CH, CF, CCI, CBr, CI, COH, CG1, COG1, CNH2, CNHG1, CNG12, COSO3H, COPO3H2, CSG1, CSOG1 o CSO2G1; Q es como en resto de formula (2); J es G1, O, CH2, CHG1, CG12, S, NH, NG1, SO, SO2, o NR; M es H, CI, Br, CH2CI, CHCI2, CCl3, CH2Br, CHBr2, CBr3 o C:::CH; L es H o A-D; A es O, S, NH, NG1, N+H2 o N+HG1; D es H, G1, R, o como los restos de formulas (3), o un resto seleccionado de la TABLA 1; cada q, r y t es independientemente 0, 1, 2, 3, 4, 5, 6 o 7; n es 0,1, 2, 3, 4, 5, 6, 7 u 8; T es un resto de formula (4); J2 es G1, O, CH2, CHG1, CG12, S, NH, NG1, SO, SO2, o NR; M2 es H, CH3, CI, Br, CH2CI, CHCI2, CCI3, CH2Br, CHBr2, CBr3, CH2OH, CH2OJö, G1, CH2OG1, CH2OR, CH2OG1OG1', G1OG1', G1OG1'OG1ö, CH2SG1, CH2NH2, CH2NHG1, CH2NG12, o C:::CH; L2 es H o A2-D2; A2 es O, S, SO, SO2, NH, NG1, N+H2, o N+HG1; D2 es H, G1, R, restos de formulas (3), o un resto seleccionado de la TABLA 1; cada u, y, j es independientemente 0, 1, 2, 3, 4, 5, 6 o 7; m es 0, 1, 2, 3, 4, 5, 6, 7 u 8; cada uno de Jö y Jö' es independientemente un resto seleccionado de la TABLA 1; cada G1, G1' y G1'ö es independientemente alquilo C1-10 lineal o ramificado, o cíclico aromático o cíclico no aromático, sustituido o no sustituido, saturado o insaturado, en donde el sustituyente opcional se puede seleccionar del grupo que consiste en oxo, OJö', COOH, R4, OH, OR4, F, CI, Br, I, NH2, NHR4, NR42, CN, SH, SR4, SO3H, SO3R4, SO2R4, OSO3R4, OR5, CO2R4, CONH2, CONHR4, CONHR5, CONR42, NHR5, OPO3H3, CONR4R5, NR4R5, y NO2; cada R4 es independientemente alquilo C1-10 no sustituido; cada R5 es independientemente acilo C1-10; y R es acilo C1-10, para preparar un medicamento para modular la actividad del receptor de androgenos (AR).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28223410P | 2010-01-06 | 2010-01-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR079975A1 true AR079975A1 (es) | 2012-03-07 |
Family
ID=44305152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110100035A AR079975A1 (es) | 2010-01-06 | 2011-01-06 | Agentes terapeuticos derivados de bisfenol u metodos para su uso, composiciones farmaceuticas y uso de los mismos |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20130109758A1 (es) |
| AR (1) | AR079975A1 (es) |
| WO (1) | WO2011082488A1 (es) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010000066A1 (en) | 2008-07-02 | 2010-01-07 | British Columbia Cancer Agency Branch | Diglycidic ether derivative therapeutics and methods for their use |
| JP5940982B2 (ja) | 2010-01-06 | 2016-06-29 | ブリティッシュ コロンビア キャンサー エージェンシー ブランチ | アンドロゲンレセプター活性調節因子としての、ビスフェノール誘導体およびその使用 |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| US9365510B2 (en) | 2012-04-16 | 2016-06-14 | British Columbia Cancer Agency Branch | Aziridine bisphenol ethers and related compounds and methods for their use |
| NZ702747A (en) | 2012-06-13 | 2017-03-31 | Incyte Holdings Corp | Substituted tricyclic compounds as fgfr inhibitors |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| LT2986610T (lt) | 2013-04-19 | 2018-04-10 | Incyte Holdings Corporation | Bicikliniai heterociklai, kaip fgfr inhibitoriai |
| SG11201509038UA (en) | 2013-05-10 | 2015-12-30 | British Columbia Cancer Agency | Ester derivatives of androgen receptor modulators and methods for their use |
| TWI641596B (zh) * | 2013-05-15 | 2018-11-21 | Ｄｉｃ股份有限公司 | 含有聯苯基骨架的環氧樹脂的製造方法 |
| SG11201601431VA (en) | 2013-09-09 | 2016-03-30 | British Columbia Cancer Agency | Halogenated compounds for cancer imaging and treatment and methods for their use |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| AU2016206412B2 (en) | 2015-01-13 | 2020-10-08 | British Columbia Cancer Agency Branch | Heterocyclic compounds for cancer imaging and treatment and methods for their use |
| SG10201913036RA (en) | 2015-02-20 | 2020-02-27 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| US10471023B2 (en) | 2015-03-12 | 2019-11-12 | British Columbia Cancer Agency Branch | Bisphenol ether derivatives and methods for using the same |
| US9874811B2 (en) | 2015-09-10 | 2018-01-23 | Samsung Electronics Co., Ltd. | Photopolymer composition for holographic recording |
| US20170298033A1 (en) * | 2016-04-15 | 2017-10-19 | The University Of British Columbia | Bisphenol derivatives and their use as androgen receptor activity modulators |
| US20180072718A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| MA46191A (fr) | 2016-09-09 | 2021-04-21 | Incyte Corp | Dérivés de pyrazolopyridine comme modulateurs de hpk1 et leurs utilisations pour le traitement du cancer |
| TW201811799A (zh) | 2016-09-09 | 2018-04-01 | 美商英塞特公司 | 吡唑并嘧啶化合物及其用途 |
| WO2018152220A1 (en) | 2017-02-15 | 2018-08-23 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| KR102332452B1 (ko) * | 2017-08-08 | 2021-11-26 | 고려대학교 산학협력단 | 아지리딘 유도체를 포함하는 이관능성 열경화성 수지 |
| AU2018315484A1 (en) | 2017-08-10 | 2020-02-27 | Boston Scientific Medical Device Limited | Heat exchange and temperature sensing device and method of use |
| US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
| LT3755703T (lt) | 2018-02-20 | 2022-10-10 | Incyte Corporation | N-(fenil)-2-(fenil)pirimidin-4-karboksamido dariniai ir susiję junginiai, kaip hpk1 inhibitoriai, skirti vėžio gydymui |
| US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| CA3093445A1 (en) | 2018-03-08 | 2019-11-28 | Incyte Corporation | Aminopyrazine diol compounds as pi3k-.gamma. inhibitors |
| US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
| EP3788046B1 (en) | 2018-05-04 | 2025-12-10 | Incyte Corporation | Salts of an fgfr inhibitor |
| EP4309737A3 (en) | 2018-05-04 | 2024-03-27 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
| WO2019226991A1 (en) | 2018-05-25 | 2019-11-28 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| ES2973117T3 (es) | 2018-09-25 | 2024-06-18 | Incyte Corp | Compuestos de pirazolo[4,3-d]pirimidina como moduladores de ALK2 y/o FGFR |
| JP7581192B2 (ja) | 2018-10-18 | 2024-11-12 | エッサ ファーマ インコーポレイテッド | アンドロゲン受容体モジュレーター及びその使用方法 |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| WO2020198712A1 (en) | 2019-03-28 | 2020-10-01 | Essa Pharma, Inc. | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CR20220097A (es) | 2019-08-06 | 2022-06-01 | Incyte Corp | Formas sólidas de un inhibidor de hpk1 |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CR20220169A (es) | 2019-10-14 | 2022-10-27 | Incyte Corp | Heterociclos bicíclicos como inhibidores de fgfr |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CN115916170A (zh) | 2020-04-17 | 2023-04-04 | 埃萨制药股份有限公司 | 固体形式的n-末端结构域雄激素受体抑制剂及其用途 |
| CA3214309A1 (en) | 2021-03-26 | 2022-09-29 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Drug discovery assay to screen for compounds |
| EP4063857A1 (en) | 2021-03-26 | 2022-09-28 | Fundació Institut de Recerca Biomèdica (IRB Barcelona) | Drug discovery assay to screen for compounds |
| EP4220159A1 (en) | 2022-01-27 | 2023-08-02 | Fundació Institut de Recerca Biomèdica (IRB Barcelona) | Drug discovery assay to screen for compounds |
| US12065494B2 (en) | 2021-04-12 | 2024-08-20 | Incyte Corporation | Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent |
| AR126101A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
| AR126102A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
| WO2023046283A1 (en) | 2021-09-22 | 2023-03-30 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | Compounds and their use in a method for modulating ar (androgen receptor) transcriptional activity |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL135932B2 (en) * | 1983-11-04 | 1986-01-31 | Politechnika Warszawska | Process for manufacturing polyfunctional polyols |
| US5753730A (en) * | 1986-12-15 | 1998-05-19 | Mitsui Toatsu Chemicals, Inc. | Plastic lenses having a high-refractive index, process for the preparation thereof and casting polymerization process for preparing sulfur-containing urethane resin lens and lens prepared thereby |
| US5155196A (en) * | 1987-06-01 | 1992-10-13 | The Dow Chemical Company | Polymer resulting from the cure of a preformed chromene-containing mixture |
| US6534621B2 (en) * | 2000-05-18 | 2003-03-18 | Dow Global Technologies Inc. | Process for manufacturing a hydroxyester derivative intermediate and epoxy resins prepared therefrom |
| US6756400B2 (en) * | 2000-08-31 | 2004-06-29 | Theravance, Inc. | Sodium channel modulators |
| US20090105349A1 (en) * | 2004-08-18 | 2009-04-23 | Warner-Lambert Company Llc | Androgen modulators |
| EP1717235A3 (en) * | 2005-04-29 | 2007-02-28 | Bioprojet | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands |
| WO2010000066A1 (en) * | 2008-07-02 | 2010-01-07 | British Columbia Cancer Agency Branch | Diglycidic ether derivative therapeutics and methods for their use |
-
2011
- 2011-01-06 AR ARP110100035A patent/AR079975A1/es unknown
- 2011-01-06 US US13/520,731 patent/US20130109758A1/en not_active Abandoned
- 2011-01-06 WO PCT/CA2011/000021 patent/WO2011082488A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011082488A1 (en) | 2011-07-14 |
| US20130109758A1 (en) | 2013-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR079975A1 (es) | Agentes terapeuticos derivados de bisfenol u metodos para su uso, composiciones farmaceuticas y uso de los mismos | |
| AR079846A1 (es) | Agentes terapeuticos derivados de bisfenol que contienen un grupo aquiral y su uso en el tratamiento del cancer | |
| ES2953575T3 (es) | Terapia de combinación para el tratamiento o la prevención de tumores | |
| ES2702128T3 (es) | Antagonista o agonista inverso de RAR para uso en el tratamiento de efectos secundarios de quimioterapia y/o terapia de radiación | |
| Lotufo et al. | Melatonin effect on endothelial cells reduces vascular permeability increase induced by leukotriene B4 | |
| ES2706063T3 (es) | Agonistas del receptor de NMDA y usos del mismo | |
| AR075396A1 (es) | Derivados de quinazolinas y composiciones farmaceuticas | |
| AR067354A1 (es) | Compuestos utiles como inhibidores de la raf quinasa | |
| AR125209A1 (es) | Compuestos anticancerígenos dirigidos a los receptores de hormonas nucleares | |
| RU2014115796A (ru) | Модуляторы ror-гамма | |
| AR043998A1 (es) | Acidos fenoxiaceticos | |
| AR085039A1 (es) | DERIVADOS DE PURINA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN LA PREPARACION DE MEDICAMENTOS PARA TRATAR ENFERMEDADES MODULADAS POR LA INHIBICION DE LA PI3K DE CLASE I Y/O mTOR | |
| AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
| EA201792652A2 (ru) | Новые производные майтанзиноида с пептидным линкером и их конъюгаты | |
| AR049399A1 (es) | Difenilimidazopirimidina e -imidazol aminas como inhibidores de b-secretasa y metodo de obtencion de los mismos | |
| DOP2001000270A (es) | Agonistas del receptor 3-adrenergico y usos de los mismos | |
| AR085471A1 (es) | Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona | |
| BRPI0510623A (pt) | compostos de derivados de prolina e morfolina | |
| AR084663A1 (es) | Preparados liofilizados de inhibidores de proteasomas | |
| PE20181357A1 (es) | Agentes inductores de apoptosis que pueden usarse para tratar el cancer y las enfermedades inmunes y autoinmunes | |
| AR074148A1 (es) | Derivados de corticoesteroides beta agonistas fosforilados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades del aparato respiratorio | |
| AR066544A1 (es) | Metodos de utilizacion de antagonistas de la vasopresina con agentes para quimioterapia con antracina para reducir la cardiotoxicidad y/o aumentar la supervivencia. composicion farmaceutica. | |
| CL2011001050A1 (es) | Compuesto 2-metil-1-(fenilsulfonil)-4-(piperazin-1-il)-1h-bencimidazol, que es ligando de 5-hidroxitriptamina-6; su composicion farmaceutica; modulador de la actividad de 5-ht6; su uso en el tratamiento de trastornos del sistema nervioso central, tal como psicosis, ansiedad, depresión, epilepsia, entre otros. | |
| AR076263A1 (es) | Composiciones y metodos para tratar cancer. uso. | |
| Lin et al. | 18β-Glycyrrhetinic acid derivatives induced mitochondrial-mediated apoptosis through reactive oxygen species-mediated p53 activation in NTUB1 cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |